Neutralizing/Blocking Antibody Products

Neutralizing Antibodies

Generally speaking, neutralizing antibody (NAb) is an antibody that able to protect the host cell from pathogens by either neutralizing or inhibiting its biological effect. This is achieved by prohibiting interactions between the viral envelope to its host cell receptor or obstructing the release of the viral genome. Studies on NAbs provide a better understanding of humoral immune responses, as well as help researchers to gain insights into the future development of immunotherapeutic.

Creative Biolabs has developed a wide variety of neutralizing antibodies that able to recognize different virus targets and formats. We can provide low endotoxin versions for researchers who want to perform in vivo assay.

MOA of Viral Neutralization

Antibodies neutralize viruses by various mechanisms:

Fig. 1 Neutralizing and non-neutralizing actions
of antibodies.^{1, 3}.

1. NAbs could bind to an epitope in the viral glycoprotein envelope, inhibiting further attachment to its host cells.
2. NAbs could bind to host cell receptors by the fab region or coreceptors (FcγR) so that virus cannot pass through.
3. NAbs could bind to a non-binding region in the virus envelope so that conformational change was inhibited and membrane fusion will not happen.
4. For some certain viruses that need low endosomal PH for conformational change, NAbs could bind to viral inside the endosome leading to inhibit the change in PH to achieve the membrane fusion. Also, NAbs can inhibit the release of the viral virion.

Blocking Antibodies

Fig. 2 The blocking antibodies and agonistic
antibodies targeting checkpoints.^{2, 3}.

For decades, in immunotherapy areas, the development of checkpoint blocking antibodies, such as targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 receptor (PD-1), have demonstrated significant promise in the treatment of malignancies.

Creative Biolabs values the studies on immune checkpoints and has already developed various neutralizing antibodies that target popular checkpoints, including PD-1, CTLA-4, LAG3, TIGIT.

What is more, Creative Biolabs offers a range of blocking antibodies that target popular surface antigens, not only including the common antigens for hematological malignancy such as CD19, CD22, CD38, BCMA, and CS1 but also for solid tumor targets like ERBB2, GD2, MUC1, etc.

For further details, please do not hesitate to contact us and see how we can help you achieve your research goal.

REFERENCES

1. Morales-Núñez, José Javier, et al. "Overview of neutralizing antibodies and their potential in COVID-19." Vaccines 9.12 (2021): 1376.
2. Meng, Lingjiao, et al. "Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks." Cell Death & Disease 15.1 (2024): 3.
3. Distributed under Open Access license CC BY 4.0, without modification.